SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

合作终止事件 - Hims & Hers与诺和诺德于2025年4月29日宣布长期合作，立即在Hims & Hers平台上销售诺和诺德FDA批准的Wegovy®捆绑产品 [2] - 诺和诺德于2025年6月23日宣布终止合作，指控Hims & Hers欺骗性推广和销售非法的Wegovy®仿制品，危害患者安全 [2] - 诺和诺德声明Hims & Hers违反法律，以"个性化"为幌子大规模销售复方药物 [2] 仿制药问题 - 诺和诺德调查发现Hims & Hers销售的仿制药活性成分由中国供应商生产，FDA从未批准，可能含有不安全成分 [2] - 这些仿制药物由远程医疗实体和复方药房销售 [2] 市场反应 - 消息公布后Hims & Hers股价在2025年6月23日下跌22.24美元/股，跌幅达34.63%，收盘价为41.98美元/股 [2] 法律行动 - Moore Law律师事务所正在调查针对Hims & Hers的潜在索赔 [1] - 股东可能无需支付费用即可寻求金钱赔偿、公司治理改革、公司补偿和法院批准的激励奖励 [3]

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=155439&from=3 CLASS PERIOD: A ...

SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and ce ...

NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=155418&from=4CLASS PERIOD: April 29, ...

NEW YORK, July 7, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period").Investors who purchased or otherwise acquired shares of Hims & Hers should contact the Firm prior to the August 25, 2025 lead plaintiff ...

公司背景 - Hims & Hers是一家提供远程医疗和在线药房服务的公司，通过直接面向消费者的平台在美国和英国销售处方药、非处方药、心理健康服务和个人护理产品 [3] 证券欺诈指控 - 公司被指控在2025年4月29日至6月23日期间就与诺和诺德的合作关系作出重大虚假和误导性陈述，并隐瞒重要事实 [4] - 具体指控包括未披露公司以欺骗方式推广和销售诺和诺德的减肥药Wegovy®，以及这种欺骗行为导致合作终止的重大风险 [4] 合作与终止事件 - 2025年4月29日，公司宣布与诺和诺德达成长期合作，立即在其平台上销售诺和诺德的Wegovy®捆绑产品 [5] - 2025年6月23日，诺和诺德终止合作，理由是公司违反法律禁止大规模销售复合药物，并以“个性化”为幌子进行欺骗性营销，危及患者安全 [5] 股价影响 - 合作终止消息公布后，公司股价在2025年6月23日下跌22.24美元，跌幅达34.63%，收盘价为41.98美元 [5]

公司诉讼事件 - 律师事务所Faruqi & Faruqi正在调查Hims & Hers Health涉嫌违反联邦证券法的行为 指控包括虚假陈述和未披露关键风险 [3][5] - 指控具体内容为Hims推广销售不合规的Wegovy仿制药 危害患者安全 且与诺和诺德的合作存在终止风险 [5] - 诺和诺德于2025年6月23日终止合作 指出Hims违反法律 销售含不安全成分的复合药物 [6] 股价影响 - 合作终止消息导致Hims股价单日暴跌34 6% 收盘价下跌22 24美元至41 98美元/股 [6] - 诉讼覆盖期为2025年4月29日至6月22日 投资者损失超过5万美元可参与集体诉讼 [1][3] 法律程序进展 - 法院将任命主要原告 需在2025年8月25日前申请 投资者可选择参与或保持观望 [7] - 律所呼吁知情者提供线索 包括 whistleblower和前员工等 [8]

公司诉讼事件 - Hims & Hers Health公司因涉嫌在2025年4月29日至6月23日期间违反《1934年证券交易法》被提起集体诉讼[1] - 诉讼指控公司在合作期间推广和销售非法的Wegovy®仿制品，危害患者安全[2] - 诺和诺德公司于2025年6月23日终止与Hims & Hers的合作关系，导致公司股价单日暴跌34%[3] 公司业务动态 - Hims & Hers是一家提供处方药、非处方药和个人护理产品的远程医疗公司[2] - 公司于2025年4月29日宣布与诺和诺德达成长期合作，开始在平台销售Wegovy®捆绑产品[2] - 诉讼称公司隐瞒了销售仿制药品的行为，导致合作终止风险未被披露[2][3] 法律程序信息 - 投资者可在2025年8月25日前申请成为集体诉讼的首席原告[1] - 根据1995年《私人证券诉讼改革法》，任何在涉诉期间购买公司证券的投资者均可申请担任首席原告[4] - 首席原告将代表全体集体成员主导诉讼进程，并可自主选择代理律所[4]